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esponsibility of InstAbstract Our previous work found that DMH1 (4-[6-(4-isopropoxyphenyl)pyrazolo [1,5-a]pyrimidin-3-
yl]quinoline) was a novel autophagy inhibitor. Here, we aimed to investigate the effects of DMH1 on
chemotherapeutic drug-induced autophagy as well as the efﬁcacy of chemotherapeutic drugs in different
cancer cells. We found that DMH1 inhibited tamoxifen- and cispcis-diaminedichloroplatinum (II)
(CDDP)-induced autophagy responses in MCF-7 and HeLa cells, and potentiated the anti-tumor activity
of tamoxifen and CDDP for both cells. DMH1 inhibited 5-ﬂuorouracil (5-FU)-induced autophagy
responses in MCF-7 and HeLa cells, but did not affect the anti-tumor activity of 5-FU for these two cell
lines. DMH1 itself did not induce cell death in MCF-7 and HeLa cells, but inhibited the proliferation of
these cells. In conclusion, DMH1 inhibits chemotherapeutic drug-induced autophagy response and the
enhancement of efﬁcacy of chemotherapeutic drugs by DMH1 is dependent on the cell sensitivity
to drugs.
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DMH1 inhibits chemotherapeutic drug-induced autophagy 3311. Introduction
Autophagy is a physiologic process which functions to digest long-
lived proteins and damaged organelles in order to sustain cellular
metabolism. It has been reported that autophagy is involved in
various diseases, including cancer, neurodegenerative diseases, patho-
gen invasion, and muscle and liver disorders1. Currently, autophagy
is considered as a “double-edged sword” that allows cells to survive
during nutrient depletion2, yet excessive autophagy leads to pro-
grammed cell death3. In most conditions, there is a robust increase of
autophagy responses in cancer cells treated by some chemotherapeu-
tics, and pharmacological inhibition of autophagy potentiates the anti-
tumor effects of chemotherapeutic drugs4,5. However, several anti-
tumor drugs such as lapatinib exert a growth inhibitory effect in
hepatoma cells via inducing autophagic cell death6.
DMH1 (4-[6-(4-isopropoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]
quinoline) is a small molecular weight chemical which has been used
as an inhibitor of bone morphogenetic protein (BMP) signal7. Recent
studies showed that DMH1 promoted neurogenesis of hiPSCs and
suppressed the growth and metastasis of lung cancer8,9. Our previous
work found that DMH1 inhibited cellular autophagy responses in a
range of cell types; the underlying mechanisms included activation of
the Akt pathway10. Since the pharmacological inhibition of autophagy
sensitizes cancer cells to various cancer therapies, in the present study,
we aimed to (1) study the effects of DMH1 on chemotherapeutic drug-
induced autophagy response, and (2) study the effects of DMH1 on the
efﬁcacy of chemotherapeutic drugs.Figure 1 DMH1 potentiates the anticancer activity of CDDP for
HeLa cells. (A) DMH1 inhibited CDDP-induced autophagy in HeLa
cells. Cells were treated with DMH1 or CDDP for 24 h. *Po0.05 vs.
Control; #Po0.05, ##Po0.01 vs. CDDP. (B) Co-application of DMH1
enhanced the ability of CDDP to reduce HeLa cell viability. *Po0.05,
**Po0.01 vs. Control; #Po0.05, ##Po0.01 vs. counterpart CDDP
dose. n¼10.2. Materials and methods
2.1. Chemical reagents and antibodies
MCF-7 and HeLa cell lines were obtained from the Type Culture
Collection of the Chinese Academy of Sciences, Shanghai, China.
cis-Diaminedichloroplatinum (II) (CDDP), 5-FU, DMH1, anti-
LC3B antibody were purchased from Sigma-Aldrich. Tamoxifen
was purchased from Tocris Bioscience (UK). MTT and dimethyl
sulfoxide (DMSO) were obtained from Amresco (USA). Dulbecco's
modiﬁed Eagle's medium (DMEM), fetal bovine serum (FBS) were
purchased from Hyclone (USA). Live/dead viability/cytotoxicity
assay kit and CFSE cell proliferation kit were obtained from
Invitrogen. In situ cell death detection (TUNEL) kit was obtained
from Roche. DAPI staining solution was purchased from Beyotime
Institute of Biotechnology (China).
2.2. Cell culture
MCF-7 and HeLa cells were grown in Dulbecco's modiﬁed Eagle's
medium/High Glucose (DMEM/High) supplemented with 10%
fetal bovine serum, 100 units/mL penicillin and 100 μg/mL
streptomycin at 37 1C, 5% CO2. After the cells grew to appropriate
density, they were treated with the chemotherapeutic drugs CDDP,
tamoxifen and 5-ﬂuorouracil, or together with DMH1 for 24 h.
The time of treatment and the concentration of agents are speciﬁed
in the ﬁgures and/or ﬁgure legends.
2.3. MTT assay
Cells were seeded in 96-well plates and treated with different
drugs for appropriate time. Then 5 mg/mL MTT was added and
incubated for 4 h at 37 1C. Medium was then removed and 200 μLof DMSO was added to dissolve the crystal. Absorbance was
measured at a wavelength of 490 nm with a plate reader (Tecan
Inﬁnite m200, Mannedorf, Switzerland).
2.4. Live and dead staining
The live/deads viability/cytotoxicity assay kit (Invitrogen) was
used to detect dead cells. Brieﬂy, cells were grown on coverslips at
a density of 3.75 104/mL and incubated overnight at 37 1C in a
humidiﬁed 5% CO2 incubator. The cells were washed with PBS
and stained according to the manufacturer's instructions. The
labeled cells were photographed under a ﬂuorescence microscope.
The live cells ﬂuoresce green and dead cells ﬂuoresce red.
2.5. TUNEL staining
After three times PBS washing, treated cells were ﬁxed with 4%
paraformaldehyde, permeabilized in 0.1% Triton X-100 sodium
citrate buffer. Then an in situ cell death detection kits (Roche)
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DAPI. The numbers of total cells and TUNEL-positive cells were
automatically counted by Image-Pro plus version. The apoptosis
rate was deﬁned as ratio of apoptotic cells to total cells.
2.6. Western blot
Detailed information was described in our previous works10.
Western blot bands were quantiﬁed by using Odyssey infrared
imaging system (LI-COR) and Odyssey v3.0 software.
2.7. Cell proliferation assay
Cell proliferation was determined by carboxyﬂuorescein diacetate
succinimidyl ester (CFSE) staining. The cells were suspended in
PBS contained 0.1% BSA and labeled for 10 min at 4 1C using
5 μmol/L CFSE. Then 4-fold volume of ice-cold medium was
added for 5 min, and the cells were washed with PBS two times.
The stained cells were allowed to grow at 37 1C, 5% CO2 for 24 h.
Then the cells were suspended in PBS, and the intensity of CFSE
staining was quantiﬁed by ﬂow cytometry (excitation: 492 nm;
emission: 517 nm). CFSE is a ﬂuorescent cell staining dye. CFSE
is retained within cells and covalently couples to intracellular
molecules. So the dye can be used to monitor cell proliferation due
to the progressive halving of CFSE ﬂuorescence within daughterFigure 2 DMH1 enhances the apoptotic induction effects of CDDP on He
death after 24 h treatment. The live cells were stained with calcein AM in gr
(B) TUNEL staining showed that DMH1 enhanced CDDP-induced cell a
control group, 3468 in CDDP group and 3615 in CDDP plus DMH1 groucells following each cell division. The cell proliferation is
negatively correlated to the intensity of ﬂuorescence.
2.8. Data analysis
Data are presented as mean7SEM. Signiﬁcance was determined
by using Student t test. Po0.05 was considered signiﬁcant.3. Results
3.1. DMH1 inhibits CDDP-induced autophagy in HeLa cells
and enhances the ability of CDDP to reduce HeLa cell viability
CDDP is widely used to treat solid tumors in clinical therapy,
although drug resistance can severely limit the effects of many
chemotherapy drugs11. It was reported that CDDP activated
autophagy in an osteosarcoma cell line and that inhibition of
autophagy enhanced CDDP-induced cell apoptosis12. Here, we
ﬁrst examined whether CDDP could induce autophagy in HeLa
cells. As shown in Fig. 1A, CDDP (20 μmol/L) treatment for 24 h
strongly activated autophagy response in HeLa cells and pretreat-
ment with DMH1 (5 μmol/L and 10 μmol/L) completely inhibited
this effect. Hao et al.9 reported that DMH1 suppressed lung
cancer cells growth and invasion. Similarly, we found that DMH1
signiﬁcantly reduced the viability of HeLa cells (Fig. 1B). SinceLa cells after 24 h treatment. (A) DMH1 enhanced CDDP-induced cell
een, and the dead cells were stained with ethidium homodimer-1 in red.
poptosis after 24 h treatment. The analyzed cell number was 6219 in
p. **Po0.01 vs. Control; ##Po0.01 vs. CDDP.
Figure 3 DMH1 potentiates the anticancer activity of tamoxifen for
MCF-7 cells. (A) DMH1 inhibited tamoxifen-induced autophagy in
MCF-7 cells. Cells were treated with DMH1 or tamoxifen for 24 h.
*Po 0.05 vs. Control; #Po0.05 vs. tamoxifen. (B) Co-application of
DMH1 enhanced the ability of tamoxifen to reduce MCF-7 cell
viability. *Po0.05, **Po0.01 vs. Control; #Po0.05, ##Po0.01 vs.
counterpart tamoxifen dose. n¼10.
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hypothesized that DMH1 could possibly increase the anti-tumor
effects of CDDP. Indeed, as shown in Fig. 1B, CDDP treatment
dose-dependently reduced HeLa cell viability, and DMH1 treat-
ment potentiated CDDP-induced inhibition of HeLa cell viability.
3.2. DMH1 increases CDDP-induced apoptotic cell death in
HeLa cells
Since DMH1 treatment potentiated CDDP-induced inhibition of
HeLa cell viability, we investigated whether apoptosis was involved
in the effects produced by DMH1 and CDDP. Firstly, we examined
the effects of DMH1 and CDDP on cell death by using live and
dead staining in HeLa cells. The calcein AM stained the live cells
green, and ethidium homodimer-1 stained the dead cells red. As
shown in Fig. 2A, DMH1 treatment had no effect on cell death, but
CDDP signiﬁcantly decreased the number of green cells and
increased the number of red cells, indicating that CDDP induced
cell death. The CDDP-induced cell death was increased when
DMH1 was further co-applied. As shown in Fig. 2B, DMH1 did
not induce apoptosis in HeLa cells, but signiﬁcantly enhanced the
ability of CDDP to induce cell apoptosis.
3.3. DMH1 inhibits tamoxifen-induced autophagy in MCF-7 cells
and enhances the ability of tamoxifen to reduce MCF-7 cell viability
Tamoxifen is effective in treating breast cancer by binding to
estrogen receptor13. We further examined whether the effects of
DMH1 as measured above also recurred in tamoxifen-treated MCF-7
cells. As shown in Fig. 3A, DMH1 (5 μmol/L and 10 μmol/L)
treatment for 24 h completely abolished the tamoxifen-induced
increase of autophagy responses in MCF-7 cells. Both DMH1 and
tamoxifen reduced MCF-7 cell viability respectively, and co-
treatment of DMH1 and tamoxifen exerted an additional inhibitory
effect on cell viability in MCF-7 cells (Fig. 3B).
3.4. DMH1 inhibited 5-FU-induced autophagy in both MCF-7
and HeLa cells but did not affect the inhibitory effects of 5-FU on
MCF-7 and HeLa cell viability
Next, we used 5-FU, which is generally sensitive to gastrointestinal
tumors, but not sensitive to breast and cervical tumors, to test
whether DMH1 enhanced the inhibitory effect of 5-FU on MCF-7
and HeLa cells. Similar to the effects of tamoxifen and CDDP, 5-FU
also induced autophagy responses in MCF-7 and HeLa cells, and
the induced autophagy was inhibited by DMH1 treatment (Fig. 4A).
However, DMH1 (5 μmol/L and 10 μmol/L) did not enhance the
inhibitory effects of 5-FU on MCF-7 and HeLa cell viability after
24, 48 and 72 h treatment (Fig. 4B).
3.5. DMH1 inhibits HeLa and MCF-7 cell proliferation
As shown in Figs. 5A–D, DMH1 reduced MCF-7 and HeLa cell
viability but did not induce cell death. To test the hypothesis that
the reduced cell viability might be due to inhibition of cell
proliferation, we further examined the effects of DMH1 on cell
proliferation with HeLa cells as example. Results showed that
DMH1 dose- and time-dependently inhibited HeLa cell prolifera-
tion (Fig. 5E and F). Since it was demonstrated that DMH1 had no
effect on the basal autophagy level10, the DMH1-inducedinhibition of cell proliferation was not related to the DMH1-
induced autophagy inhibition.4. Discussion
Our previous study evidences that DMH1 is a novel autophagy
inhibitor which inhibits starvation, AICAR (aminoimidazole
carboxamide ribonucleotide)- and rapamycin-induced autophagy
by activating AKT/mTOR pathway10, but whether DMH1 can
also inhibit the autophagy triggered by chemotherapeutic drugs
and/or enhance the antitumor activity of chemotherapeutic
drugs remained unclear. In the present study, we found for the
ﬁrst time that DMH1 inhibits CDDP, tamoxifen and 5-FU induced
Figure 4 DMH1 inhibited 5-FU-induced autophagy in MCF-7 and HeLa cells but did not affect the inhibitory effects of 5-FU on MCF-7 and
HeLa cell viability after 24, 48 and 72 h treatment. (A) DMH1 inhibited 5-FU-induced autophagy in HeLa cells. *Po0.05 vs. Control. #Po0.05,
##Po0.01 vs. 5-FU. (B) DMH1(5 and 10 μmol/L) did not affect the inhibitory effects of 5-FU on HeLa cell viability after 24, 48 and 72 h
treatment. **Po0.01 vs. Control. n¼10. (C) DMH1 inhibited 5-FU-induced autophagy in MCF-7 cells. *Po0.05 vs. Control. #Po0.05 vs. 5-FU.
(D) DMH1 (5 and 10 μmol/L) did not affect the inhibitory effects of 5-FU on MCF-7 cell viability after 24, 48 and 72 h treatment. **Po0.01 vs.
Control. NS, no signiﬁcance vs. counterpart drug dose. n¼10.
Yue Sheng et al.334autophagy responses and potentiates the antitumor effects of
CDDP and tamoxifen in HeLa and MCF-7 cells.
Autophagy plays a complicated role in tumorigenesis and treat-
ment responsiveness. On the one hand, induction of autophagy seems
to be beneﬁcial for cancer prevention and induction of autophagic
cell death is as a therapeutic strategy. On the other hand, inhibiting
autophagy can enhance the efﬁcacy of anticancer therapies. Several
studies have demonstrated that inhibition of autophagy sensitizes
cancer cells to chemotherapy and gene therapy14,15. However,
many factors involved in the relationship between autophagy and
chemosensitivity were still undetermined. Since DMH1 inhibited
autophagy, we examined whether it inﬂuenced the effects of
chemotherapeutic drugs by using different cell lines and different
drugs. In the present study, we used MCF-7 and HeLa cancer
cells which were sensitive to tamoxifen and CDDP respectively.
Tamoxifen and CDDP induced autophagy in MCF-7 and HeLa cells
and inhibited the cell viability in a dose- and time-dependent manner.Co-application of DMH1 signiﬁcantly potentiated the anticancer
activity of tamoxifen and CDDP in MCF-7 and HeLa cells.
Furthermore, we treated HeLa and MCF-7 cells with 5-FU which
was not sensitive to these two cell lines. We found that 5-FU induced
autophagy in HeLa and MCF-7 cells and dose- and time-dependently
inhibited the cell viability, although DMH1 showed no enhancing
effect for 5-FU in these cells. Abedin et al.16 found that autophagy
inhibition enhanced apoptosis in camptothecin-treated primary and
noninvasive breast cell lines, but not metastatic breast cell lines.
These results, together with our present data, implied that the
relationship between autophagy and chemosensitivity was compli-
cated and it could not be simply concluded that autophagy inhibition
enhanced chemosensitivity under all conditions. Our previous work
showed that the autophagy inhibitor 3-methyladenine induced cell
death but its interaction with chemotherapeutic drugs was indepen-
dent of autophagy17. Therefore, the role of autophagy inhibition in
chemotherapy needs further elucidating.
Figure 5 DMH1 inhibits HeLa and MCF-7 cell proliferation. (A) DMH1 reduced HeLa cells viability. **Po0.01 vs. Control. n¼10. (B)
Representative photos of live and dead staining by which the live cells ﬂuoresce green and death cells ﬂuoresce red. (C) DMH1 reduced MCF-7
cells viability. *Po0.05, **Po0.01 vs. Control. n¼10. (D) Representative photos of live- and dead staining by which the live cells ﬂuoresce
green and death cells ﬂuoresce red. (E) DMH1 dose-dependently inhibited HeLa cell proliferation. *Po0.05, **Po0.01 vs. Control. n¼4. (F) The
time course of DMH1-inhibited cell proliferation in HeLa cells. **Po0.01 vs. Control. n¼4.
DMH1 inhibits chemotherapeutic drug-induced autophagy 335Besides the inhibitory effect on autophagy, DMH1 also has
other actions, so we could not exclude the possibility that DMH1
sensitized cancer cells to chemotherapy through targeting other
signal pathways. It was reported that BMPs were aberrantly
expressed in many types of carcinoma cells including prostate,
lung, breast, gastric and ovarian18–21, overexpression of BMP-2 in
non-small cell lung cancer cell lines signiﬁcantly enhanced tumor
growth in a mouse model of lung cancer22. Conversely, the BMP
inhibitor noggin and DMH1 dramatically reduced lung tumor
growth in subcutaneous xenograft mouse models9,23, suggesting
that DMH1 increased the efﬁcacy of anti-tumor drugs which might
be due to its role in blocking BMP signal. On the other hand, we
found DMH1 inhibited intracellular ATP levels in L6 cells24.
Targeting cancer cell mitochondria to deplete ATP was an
effective therapeutic approach25. ATP depletion stimulated
by norcantharidin induced prostate cancer cells apoptosis and
inhibited the proliferation-relate genes PCNA, Ki67 and p27expression in gallbladder carcinoma cells26,27. So the effect of
DMH1 to decrease cellular ATP levels might also be involved.
In conclusion, DMH1 inhibits chemotherapeutic drug-induced
autophagy response. The enhancement of chemotherapeutic drug
efﬁcacy by DMH1 is dependent on the cell sensitivity to the drugs,
not the autophagy inhibition action.Acknowledgments
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